On Demand Webinars
Clinical Biobanking: Patient Engagement in Drug Development: What Patients Have to Offer and What They Want You to KnowContains 1 Component(s)
This webinar will explore iConquerMS and other Project programs in the context of biorepositories, patient data, and advocacy.
Building Better iPSC Models of Human Disease and DevelopmentContains 1 Component(s)
Since their initial generation in 2007 human induced pluripotent stem cells (hiPSC) have been used to model human development and disease progression, for drug screening and for toxicology testing. It is now possible to reprogram a wide range of cell types allowing a greater diversity of hiPSC to be generated and increasing the availability of hiPSC containing either specific mutations or from subjects with diseases that do not have known genotype.
Mitigation and identification of aggregation and nonspecific reactivity interference in high-throughput screeningContains 2 Component(s) Recorded On: 06/07/2018
Compound-mediated assay interference and bioassay promiscuity are significant burdens in drug and chemical probe discovery. Pursuing artifacts or poorly tractable, nonselective chemical matter from real and virtual high-throughput screening (HTS) can waste significant scientific resources and can lead to tenuous scientific conclusions when used in subsequent studies.
Using AI and IoT to Accelerate ResearchContains 2 Component(s) Recorded On: 05/08/2018
In this webinar, we will explore how new technologies can be used to accelerate scientific research. Join us for an in-depth look at how we can also overcome challenges by practically incorporating new tech into research processes to uncover and decipher hidden confounding variables.
Identifying new allosteric sites on PTP1B using fragment-based tether scanningContains 1 Component(s) Recorded On: 02/07/2018
We have been applying a disulfide-tethering fragment-based approach to identify and characterize new binding and allosteric sites on PTP1B. Here we report our progress to date, and show that this “Tether Scanning” approach has allowed us to identify new binding sites on PTP1B, as well as new disulfide fragments that modulate PTP1B activity.
Inflammation-on-a-chip – High-throughput microscale arrays for human neutrophil swarmingContains 1 Component(s) Recorded On: 02/07/2018
Neutrophil swarms protect healthy tissues by sealing off sites of infection. In the absence of swarming, microbial invasion of surrounding tissues can result in severe infections. Recent observations in animal models have shown that swarming requires rapid neutrophil responses and well-choreographed neutrophil migration patterns.
Tumor Organoids for Therapeutic Discovery and Personalized MedicineContains 1 Component(s) Recorded On: 02/07/2018
This presentation will discuss our recent innovative tumor organoid models of various cancers, which we have engineered for 3D HCS drug discovery targeting EMT. Our tumor organoid models feature an innovative dual fluorescent biomarker reporter of EMT that can effectively track the forward and reverse EMT transition in live tumor organoids.
Routine lab automation with culture dishes made easy - How the PetriJet platform technology helps to makes drinking water analysis faster and betterContains 1 Component(s) Recorded On: 02/07/2018
Digitalization, Automation and Miniaturization currently change the way we live and work. It also affects daily work in laboratories. The disruptive development of new technologies such as open source automation technology, the Internet of Things (IoT) and 3D-printing offer endless possibilities for an in-house engineering of new laboratory devices which are compact, adaptable and smart.
NGS-based Genome-wide Genetic Screens for RNA Processing RegulatorsContains 1 Component(s) Recorded On: 02/07/2018
High throughput genetic and chemical screens have been powerful tools to comprehensively identify regulators in specific cellular pathways or drug leads in both industry and academia. However, most screens rely on one or a few functional readouts, even with so-called high content screens. We have developed a robust and fully automatable screen platform that couples with NGS (next-generation sequencing) to monitor the expression of hundred-to-thousand endogenous genes associated with a phenotype without need to purify RNA.
SLAS2018 Innovation Award Finalist: Combinatorial Drug Screening, High-Throughput Flow Cytometry, and Agile Integration: a Modern Platform for Personalized Treatment Discovery for Cancer PatientsContains 1 Component(s) Recorded On: 02/07/2018
Our mission at Notable Labs is to identify actionable, personalized treatments for cancer patients. To help us achieve this goal, we have developed a platform that combines combinatorial testing, drug repurposing, and several high-throughput technologies to automate our phenotypic screens on primary patient samples. Our current focus is in acute myeloid leukemia (AML) and other hematological malignancies, although the platform and assay can be extended to other indications.